Clinical trial
Temozolomide and Radiation Therapy in Treating Patients With Gliomas
NCT00114140 · Radiation Therapy Oncology Group, Other · Completed
Key facts
| NCT number | NCT00114140 |
|---|---|
| Title | Temozolomide and Radiation Therapy in Treating Patients With Gliomas |
| Official title | A Phase II Study of a Temozolomide-Based Chemoradiotherapy Regimen for High-Risk Low-Grade Gliomas |
| Lead sponsor | Radiation Therapy Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH NRG Oncology |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Drug, Radiation |
| Interventions | Temozolomide, Radiation therapy |
| Enrollment | 136 |
| Start date | Jan 1, 2005 |
| Primary completion | Feb 1, 2013 |
| Completion | May 20, 2022 |
| First posted | Jun 14, 2005 |
| Last update posted | Jul 8, 2024 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: